search
for
 About Bioline  All Journals  Testimonials  Membership  News


International Journal of Reproductive BioMedicine
Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences of Yazd
ISSN: 1680-6433
EISSN: 1680-6433
Vol. 1, No. 1, 2003, pp. 1-6
Bioline Code: rm03001
Full paper language: English
Document type: Research Article
Document available free of charge

International Journal of Reproductive BioMedicine, Vol. 1, No. 1, 2003, pp. 1-6

 en Is There a Place for Round and Elongated Spermatids Injection inAssisted Reproduction?
Asimakopoulos, Byron; Nikolettos, Nikos & Al-Hasani, Safa

Abstract

Spermatids are the earliest male germ cells with one set of haploid chromosomes. After experiments, mainly in rodents, the spermatid injection was introduced in human assisted reproduction to the treatment of men with non-obstructive azoospermia. Spermatid injection is a technique with particular difficulties that may negatively influence the outcome. The identification, isolation and the assessment of viability, especially for round spermatids, require intensive work and considerable experience. Up to date, it appears that the rates of fertilization and implantation with round spermatid injection are dramatically low and significantly less compared to the use of elongated spermatid injection. The extremely low fertilization potency of the round spermatids led to attempts for their in-vitro culture and maturation. The immaturity of round and elongated spermatids has raised concerns regarding the potential genetic risk for the offspring. Under these facts, a reconsideration of the use of spermatids in assisted human reproduction is necessary.

 
© Copyright 2003 - Iranian Journal of Reproductive Medicine
Alternative site location: http://www.ijrm.ir

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil